158 related articles for article (PubMed ID: 15869404)
1. Receptor-targeted cancer therapy.
Richter M; Zhang H
DNA Cell Biol; 2005 May; 24(5):271-82. PubMed ID: 15869404
[TBL] [Abstract][Full Text] [Related]
2. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer.
Baselga J; Arteaga CL
J Clin Oncol; 2005 Apr; 23(11):2445-59. PubMed ID: 15753456
[TBL] [Abstract][Full Text] [Related]
3. Rational bases for the development of EGFR inhibitors for cancer treatment.
Bianco R; Gelardi T; Damiano V; Ciardiello F; Tortora G
Int J Biochem Cell Biol; 2007; 39(7-8):1416-31. PubMed ID: 17596994
[TBL] [Abstract][Full Text] [Related]
4. The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R
Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
[TBL] [Abstract][Full Text] [Related]
5. Targeting epidermal growth factor receptor signaling: early results and future trends in oncology.
Lage A; Crombet T; González G
Ann Med; 2003; 35(5):327-36. PubMed ID: 12952019
[TBL] [Abstract][Full Text] [Related]
6. ErbB receptors and signaling pathways in cancer.
Hynes NE; MacDonald G
Curr Opin Cell Biol; 2009 Apr; 21(2):177-84. PubMed ID: 19208461
[TBL] [Abstract][Full Text] [Related]
7. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer.
Mendelsohn J; Baselga J
J Clin Oncol; 2003 Jul; 21(14):2787-99. PubMed ID: 12860957
[TBL] [Abstract][Full Text] [Related]
8. An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review).
Ferrer-Soler L; Vazquez-Martin A; Brunet J; Menendez JA; De Llorens R; Colomer R
Int J Mol Med; 2007 Jul; 20(1):3-10. PubMed ID: 17549382
[TBL] [Abstract][Full Text] [Related]
9. New insights into anti-HER-2 receptor monoclonal antibody research.
Kumar R; Mandal M; Vadlamudi R
Semin Oncol; 2000 Dec; 27(6 Suppl 11):84-91; discussion 92-100. PubMed ID: 11236033
[TBL] [Abstract][Full Text] [Related]
10. Oncogenic growth factor receptors: implications for signal transduction therapy.
Mosesson Y; Yarden Y
Semin Cancer Biol; 2004 Aug; 14(4):262-70. PubMed ID: 15219619
[TBL] [Abstract][Full Text] [Related]
11. Emerging strategies for ErbB ligand-based targeted therapy for cancer.
Tsujioka H; Yotsumoto F; Shirota K; Horiuchi S; Yoshizato T; Kuroki M; Miyamoto S
Anticancer Res; 2010 Aug; 30(8):3107-12. PubMed ID: 20871027
[TBL] [Abstract][Full Text] [Related]
12. Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu).
Reid A; Vidal L; Shaw H; de Bono J
Eur J Cancer; 2007 Feb; 43(3):481-9. PubMed ID: 17208435
[TBL] [Abstract][Full Text] [Related]
13. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
[TBL] [Abstract][Full Text] [Related]
14. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): simple drugs with a complex mechanism of action?
Normanno N; Maiello MR; De Luca A
J Cell Physiol; 2003 Jan; 194(1):13-9. PubMed ID: 12447985
[TBL] [Abstract][Full Text] [Related]
15. Advances in targeting human epidermal growth factor receptor-2 signaling for cancer therapy.
Meric-Bernstam F; Hung MC
Clin Cancer Res; 2006 Nov; 12(21):6326-30. PubMed ID: 17085641
[TBL] [Abstract][Full Text] [Related]
16. Clinical implications of EGFR expression in the development and progression of solid tumors: focus on non-small cell lung cancer.
Ettinger DS
Oncologist; 2006 Apr; 11(4):358-73. PubMed ID: 16614231
[TBL] [Abstract][Full Text] [Related]
17. Novel approaches with targeted therapies in bladder cancer. Therapy of bladder cancer by blockade of the epidermal growth factor receptor family.
Bellmunt J; Hussain M; Dinney CP
Crit Rev Oncol Hematol; 2003 Jun; 46 Suppl():S85-104. PubMed ID: 12850530
[TBL] [Abstract][Full Text] [Related]
18. Effects of trastuzumab on epidermal growth factor receptor-dependent and -independent human colon cancer cells.
Kuwada SK; Scaife CL; Kuang J; Li X; Wong RF; Florell SR; Coffey RJ; Gray PD
Int J Cancer; 2004 Mar; 109(2):291-301. PubMed ID: 14750183
[TBL] [Abstract][Full Text] [Related]
19. Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells.
Menendez JA; Vellon L; Lupu R
Med Hypotheses; 2005; 64(5):997-1001. PubMed ID: 15780499
[TBL] [Abstract][Full Text] [Related]
20. Interference with EGFR signaling: paradigm for improving radiation response in cancer treatment.
Raben D; Bianco C; Helfrich B; Weng E; Ciardiello F; Harari P
Expert Rev Anticancer Ther; 2002 Aug; 2(4):461-71. PubMed ID: 12647989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
